Interchangeabilité des médicaments à libération modifiée

Abstract

The introduction of new dosage forms, inspired producers in the pharmaceutical field especially in recent years. Much of this innovation has been dedicated to the modified release . These were the subject of our work as they confer several benefits to patients, including reducing the number of doses per day and therefore adverse effects which ensures to the sick especially polymedicated, the importance given to these forms requires a of their dispensing by pharmacists to ensure the therapeutic objective, the problem in with these products is their interchangeability which in most cases does not follow appropriate and defined rules. That what motivated us to form a initiative list that ranks modified release drugs registered in Algeria to products with eligible interchangeability and whose interchangeability is uncertain by comparing them to what currently exists in France and the United states, it allowed us to classify 100 products 133 (75%). This work can a blank for the regulatory authority to achieve a comprehensive support on the basis of study.